The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

• DOI: 10.1038/srep41309
• Publication Date: 2017-01-25T10:25:04Z
• Authors: Eduardo Tormo; Anna Adam-Artigues; Sandra Ballester; Begoña Pineda; Sandra Zazo; Paula González-Al...; Joan Albanell; Ana Rovira; Federico Rojo; Ana Lluch; Pilar Eroles
• Keywords: Viability assay

Abstract A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, their target gene CCNE2 seems play an important role in therapy. Cell viability was evaluated treated BT474 wt (sensitive), BT474r (acquired resistance), HCC1954 (innate MDA-MB-231 (HER2−) cell lines, the expression miR-26a, miR-30b, genes measured. decreased by 60% were significantly overexpressed (~3-fold, p = 0.003 0.002, respectively) after treatment, but no differences observed resistant control lines. Overexpression sensitized cells ( 0.01) , treatment 0.032), significant changes sensitive line. When silenced sensitivity increased 0.03). Thus, molecular mechanism action line may be regulated overexpression might acquired given that diminished when silenced.